Literature DB >> 32330284

The cellular prion protein beyond prion diseases.

Giorgia Manni1, Victoria Lewis2, Matteo Senesi2, Giovanni Spagnolli3, Francesca Fallarino1, Steven J Collins4, Sophie Mouillet-Richard5, Emiliano Biasini3.   

Abstract

The cellular prion protein (PrPC), a cell surface glycoprotein originally identified for its central role in prion diseases (also called transmissible spongiform encephalopathies), has recently been implicated in the pathogenesis of other neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases, by acting as a toxicity-transducing receptor for different misfolded protein isoforms, or in some case by exerting neuroprotective effects. Interestingly, PrPC has also been reported to play unexpected functions outside the nervous system, for example by contributing to myelin homeostasis, regulating specific processes of the immune system and participating in various aspects of cancer progression. Collectively, these observations point to a much broader role for PrPC in physiological and disease processes than originally assumed. In this manuscript, we provide an overview of what is known about the role of PrPC beyond prion disorders and discuss the potential implications of targeting this protein in different diseases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32330284     DOI: 10.4414/smw.2020.20222

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  4 in total

Review 1.  Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.

Authors:  Behnam Mohammadi; Feizhi Song; Andreu Matamoros-Angles; Mohsin Shafiq; Markus Damme; Berta Puig; Markus Glatzel; Hermann Clemens Altmeppen
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

2.  Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein.

Authors:  Jacqueline Bernardino-Sgherri; Capucine Siberchicot; Frédéric Auvré; Didier Busso; Clémentine Brocas; Ghazi El Masri; Anna Lioutsko; Federica Ferri; J Pablo Radicella; Paul-Henri Romeo; Anne Bravard
Journal:  Oncogene       Date:  2021-03-25       Impact factor: 9.867

3.  Anti-PrP monoclonal antibody as a novel treatment for neurogenesis in mouse model of Alzheimer's disease.

Authors:  Ruolin Li; Ming Ren; Yingxin Yu
Journal:  Brain Behav       Date:  2021-10-21       Impact factor: 2.708

4.  Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma.

Authors:  Matteo Bianchini; Maria Anita Giambelluca; Maria Concetta Scavuzzo; Gregorio Di Franco; Simone Guadagni; Matteo Palmeri; Niccolò Furbetta; Desirée Gianardi; Niccola Funel; Claudio Ricci; Raffaele Gaeta; Luca Emanuele Pollina; Alfredo Falcone; Caterina Vivaldi; Giulio Di Candio; Francesca Biagioni; Carla Letizia Busceti; Luca Morelli; Francesco Fornai
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.